Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control

Author:

Lu Li12ORCID,Xie Mingqi3456ORCID,Yang Bo1278,Zhao Wen-bin2ORCID,Cao Ji1289ORCID

Affiliation:

1. Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

2. Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China.

3. Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China.

4. Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, Hangzhou, Zhejiang 310024, China.

5. School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310024, China.

6. Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang 310024, China.

7. School of Medicine, Hangzhou City University, Hangzhou, Zhejiang 310015, China.

8. Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, Hangzhou, China.

9. Cancer Center, Zhejiang University, Hangzhou, China.

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy is a promising and precise targeted therapy for cancer that has demonstrated notable potential in clinical applications. However, severe adverse effects limit the clinical application of this therapy and are mainly caused by uncontrollable activation of CAR-T cells, including excessive immune response activation due to unregulated CAR-T cell action time, as well as toxicity resulting from improper spatial localization. Therefore, to enhance controllability and safety, a control module for CAR-T cells is proposed. Synthetic biology based on genetic engineering techniques is being used to construct artificial cells or organisms for specific purposes. This approach has been explored in recent years as a means of achieving controllability in CAR-T cell therapy. In this review, we summarize the recent advances in synthetic biology methods used to address the major adverse effects of CAR-T cell therapy in both the temporal and spatial dimensions.

Publisher

American Association for the Advancement of Science (AAAS)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3